India
/
Software
/
NSEI:QUICKHEAL

Does Quick Heal Technologies' (NSE:QUICKHEAL) CEO Salary Compare Well With The Performance Of The Company?

February 17, 2021

The CEO of Quick Heal Technologies Limited (NSE:QUICKHEAL) is Kailash Katkar, and this article examines the executive's compensation against the backdrop of overall company performance. This analysis will also assess whether Quick Heal Technologies pays its CEO appropriately, considering recent earnings growth and total shareholder returns.

View our latest analysis for Quick Heal Technologies

Comparing Quick Heal Technologies Limited's CEO Compensation With the industry

Our data indicates that Quick Heal Technologies Limited has a market capitalization of ₹9.8b, and total annual CEO compensation was reported as ₹13m for the year to March 2020. We note that's a decrease of 9.2% compared to last year. We note that the salary portion, which stands at ₹11.9m constitutes the majority of total compensation received by the CEO.

On comparing similar-sized companies in the industry with market capitalizations below ₹15b, we found that the median total CEO compensation was ₹4.8m. Hence, we can conclude that Kailash Katkar is remunerated higher than the industry median. Furthermore, Kailash Katkar directly owns ₹2.9b worth of shares in the company, implying that they are deeply invested in the company's success.

Component	2020	2019	Proportion (2020)
Salary	₹12m	₹12m	90%
Other	₹1.3m	₹2.7m	10%
Total Compensation	₹13m	₹15m	100%

Talking in terms of the industry, salary represents all of total compensation among the companies we analyzed, while other remuneration is, interestingly, completely ignored. Quick Heal Technologies sets aside a smaller share of compensation for salary, in comparison to the overall industry. If salary dominates total compensation, it suggests that CEO compensation is leaning less towards the variable component, which is usually linked with performance.

ceo-compensation — NSEI:QUICKHEAL CEO Compensation February 18th 2021

A Look at Quick Heal Technologies Limited's Growth Numbers

Over the last three years, Quick Heal Technologies Limited has shrunk its earnings per share by 2.8% per year. It saw its revenue drop 5.1% over the last year.

Its a bit disappointing to see that the company has failed to grow its EPS. This is compounded by the fact revenue is actually down on last year. It's hard to argue the company is firing on all cylinders, so shareholders might be averse to high CEO remuneration. We don't have analyst forecasts, but you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Has Quick Heal Technologies Limited Been A Good Investment?

With a three year total loss of 44% for the shareholders, Quick Heal Technologies Limited would certainly have some dissatisfied shareholders. Therefore, it might be upsetting for shareholders if the CEO were paid generously.

In Summary...

As previously discussed, Kailash is compensated more than what is normal for CEOs of companies of similar size, and which belong to the same industry. Disappointingly, share price gains over the last three years have failed to materialize. Arguably worse, we've been waiting for positive EPS growth for the last three years. Considering such poor performance, we think shareholders might be concerned if the CEO's compensation were to grow.

While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. We did our research and spotted 1 warning sign for Quick Heal Technologies that investors should look into moving forward.

Switching gears from Quick Heal Technologies, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.

When trading Quick Heal Technologies or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

Valuation is complex, but we're here to simplify it.

Discover if Quick Heal Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

mitchell_lawler

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

199

zoe_vi5fn3d

Any moat with an opt-out clause for your competitors is just a fence around your own garden.

connor_iwn1g3d

Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.

Andrew Legget

Great earnings season, but are the earnings real?

At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.

Aug 28, 2026

About NSEI:QUICKHEAL

Quick Heal Technologies

Engages in the provision of security software products and solutions to consumers, small businesses, government establishments, and corporate houses in India and internationally.

See The Free Research Report